2008 brought new information for people with colorectal cancer and those at risk for it. The role of KRAS tumor mutations was a major step forward for personalized medicine. New screening guidelines provided additional resources and guidance for colorectal cancer prevention.
ESA use was restricted further and information was developed to help patients make choices about using the medicines to manage anemia associated with chemotherapy. Flat and highly dangerous colorectal cancer lesions that are different from polyps were uncovered.
The Genetic Information Non-Discrimination Act was passed.
While there were steps forward in research and screening, nearly 50,000 Americans and half a million people worldwide died of colon or rectal cancer. Read the rest of this entry »



